Share our Vision
developing therapeutics for AML
and other life-threatening leukemias
Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia.
Our primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients.
Our clinical program is based around three druggable intervention points with potential to improve safety and efficacy of current AML combination therapies.
Focused on Acute Myeloid Leukemia and other blood cancers
Lead programmes in the clinic, each targeting a key regulator of cancer
Source: American Cancer Society: Cancer Facts and Figures 2017.
|44% of cases|
|43% of cases|
Chief Financial Officer
Mr Lazzaretti has extensive experience in the healthcare and pharmaceutical industry and joined Rasna from Pharmentis Srl, a spin-off from Teva Ratiopharm, where he served as Group Finance Director from 2011. Prior to this, Mr Lazzaretti was Executive Director at Alliance Boots Healthcare, and held senior positions at Accenture, SNIA Spa and Fiat Group.
Mr Lazzaretti has a Bachelor of Science (BSc Hons) in Accounting and Finance from the University of Turin, Italy, was awarded a Master in Business Administration (MBA) from Bocconi University, Milan and studied Corporate Finance at the London Business School.
Brunangelo Falini MD
University of Perugia
Roberto Pellicciari PhD
University of Perugia
Alessandro Padova PhD
The original drug dactinomycin (Cosmegen®) has shown complete remission in 40% of AML patients (N=10)Learn more
Novel inhibitors of LSD-1, a pathway that blocks differentiation and confers a poor prognosis in AML. LSD-1 has already been identified as a important druggable targetLearn more
A first in class NCE for NPM1, currently at the pre-clinical stage, this orally available small molecule has the potential to treat refractory AML with reduced toxicity.Learn more
420 Lexington Avenue, Suite 2525
New York, NY 10170
firstname.lastname@example.org \\ Tel: [+1] (646) 396-4080
55 Park Lane
London W1K 1NA
email@example.com \\ Tel: [+44] (0) 207 495 2379
Pennsylvania Biotechnology Center of Bucks County
3805 Old Easton RD
Doylestown, PA 18902-8400
firstname.lastname@example.org \\ Tel: [+1] (215) 589-6300